^
Association details:
| Biomarker: | HER-2 V777L |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Intrinsic HER2 V777L mutation mediates resistance to trastuzumab in a breast cancer patient
Published date:
11/29/2016
Excerpt:
These results suggest that HER2 V777L mutation is responsible for, and a predictive marker of, trastuzumab resistance. This is the first report to show that HER2 V777L is coincident with HER2-amplification in breast cancers that have developed trastuzumab resistance.
DOI:
10.1007/s12032-016-0857-2
